Adolfo López de Munain

Adolfo López de Munain
Instituto de Investigación Sanitaria Biodonostia (IIS Biodonostia), Spain
Therapeutic targeting of MBNL microRNAs as innovative treatments for myotonic dystrophy
Principal investigator

• Ruben Artero
  University of Valencia, Spain
  Poject leader

• Matthew Wood
  University of Oxford, UK

• Javier Ramón Azcón
  Institute for Bioengineering of Catalonia (IBEC), Spain

• Geneviève Gourdon
  Institut IMAGINE, France

Dr. López de Munain is the current PI of the Donostia group at the Center for Biomedical Network Research on Neurodegenerative Diseases (CIBERNED) driven by the Carlos III Health Institute and member of its Steering Committee and Director of Donostia Node of Basque Biobank of Tissues and DNA for Research. He is also a member of the Board of the Matia Foundation and the Council of the Division of Health and Quality of Life of TECNALIA.

In addition, he is co-founder of MIRAMOON Pharma, a start-up specialized in drug discovery and MIAKER DEVELOPMENTS SL a company devote to scientific services to make possible the translation of scientific knowledge to the companies.

https://www.linkedin.com/in/adolfo-lopez-de-munain-arregui-bb0328102/

The common line of his work has been neurogenetic research with contributions in several clinical fields of Neurology. In addition to the main line in neuromuscular diseases, he actively participated in the design and implementation of other lines of clinical and molecular research in neurodegenerative diseases (frontotemporal dementias, prion diseases, ALS and Parkinson's disease among others) in multiple sclerosis and organized REIG (Spanish Network Multidisciplinary Research Group of Glioblastoma).

IIS Biodonostia
Paseo Dr. Begiristain, s/n
20014 Donostia-San Sebastián, Gipuzkoa
Spain

https://www.biodonostia.org